Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 3/20 | 0.43 |
| ▸ | ANPEP | P15144 | 3/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | LAP3 | P28838 | 6/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.42 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.42 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4693087 | 0.91 | CSNK1E (0.48) | CSNK1EF2MMP2EPHX1BCHE | |
| SCHEMBL14627960 | 0.87 | CSNK1E (0.53) | CSNK1EF2MMP2EPHX1BCHE | |
| SCHEMBL7300383 | 0.87 | CSNK1E (0.54) | CSNK1EF2MMP2EPHX1BCHE | |
| SCHEMBL496056 | 0.86 | ANPEP (0.55) | CSNK1EF2EPHX1BCHEANPEP | |
| SCHEMBL3347864 | 0.86 | ANPEP (0.55) | CSNK1EF2EPHX1BCHEANPEP | |
| SCHEMBL4044665 | 0.86 | ANPEP (0.55) | CSNK1EF2EPHX1BCHEANPEP | |
| SCHEMBL4696783 | 0.86 | ANPEP (0.55) | CSNK1EF2EPHX1BCHEANPEP | |
| Hydrochloric Acid SCHEMBL7310009 | 0.85 | CSNK1E (0.53) | CSNK1EF2MMP2EPHX1BCHE | |
| Hydrochloric Acid SCHEMBL5219517 | 0.84 | ANPEP (0.54) | CSNK1EF2EPHX1BCHEANPEP | |
| Hydrochloric Acid SCHEMBL496686 | 0.84 | ANPEP (0.54) | CSNK1EF2EPHX1BCHEANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692143-B1 | TRICYCLIC INDOLE HYDROXYETHYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-20060229302-A1 | Tricyclic indole derivatives and their use in the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229302-A1 | Tricyclic indole derivatives and their use in the treatment of alzheimer's disease | BACE2, BACE1, PSEN2 | CSNK1E 580/4885F2 4637/4885MMP2 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.